BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Market Closed - Borsa Italiana 04:04:59 2024-06-19 pm EDT | ||
| 34.65 EUR | 0.00% |
|
| Current month | +24.77% | ||
| 1 month | +49.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-19 | 34.65 | +0.81% |
| 24-06-18 | 34.37 | +1.48% |
| 24-06-17 | 33.87 | +1.96% |
| 24-06-14 | 33.22 | -1.19% |
| 24-06-13 | 33.62 | +4.51% |
Real-time Borsa Italiana
Last update June 19, 2024 at 04:04 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| S33389 | |
| ISIN | DE000SU58T38 |
| Date issued | 2023-12-28 |
| Strike | 526.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 34.87 € |
|---|---|
| Lowest since issue | 7.14 € |
| Spread | 0.2 € |
| Spread % | 0.58% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5
USD
Average target price
855.4
USD
Spread / Average Target
-4.05%
- Stock Market
- Certificates
- S33389 Certificat
